Published: Apr 13, 2021, 19:51 IST | Updated: Apr 13, 2021, 19:51 IST
The moves come after European regulators said earlier this month they had found a possible link between AstraZeneca's COVID-19 vaccine and a similar rare blood clotting problem that led to a small number of deaths.